Advertisement

European Journal of Nuclear Medicine

, Volume 20, Issue 2, pp 119–122 | Cite as

The role of gallium-67 tumour scintigraphy in patients with small, non-cleaved cell lymphoma

  • Dirk Sandrock
  • Secondo Lastoria
  • Ian T. Magrath
  • Ronald D. Neumann
Original Article

Abstract

Two hundred and thirty-four scintigraphic studies were performed in 34 patients (27 men, 7 women, age 17.3±7.7 years) with small, non-cleaved cell lymphoma who had follow-up for 3–96 months (mean 21.6±21.7 months). Whole-body scintigraphy was performed 48–72 h following i.v. injection of 370 MBq gallium-67 citrate. “Gold standards” for truth determinations were surgery, autopsy, histology, axial x-ray computed tomography, magnetic resonance imaging, ultrasonography and clinical follow-up. Overall, 181 of 234 studies were true negative. Eighty proven sites of disease had true positive 67Ga uptake (in 21 patients/37 studies). Nineteen sites (in 12 patients/15 studies) were false positive. In addition, 31 benign lesions were detected and interpreted correctly in terms of non-malignancy. Ten lymphoma sites (in 6 patients/10 studies) were missed by scintigraphy. Overall, sensitivity of gallium scintigraphy was 89% when calculated by sites and 79% when calculated by studies. Corresponding specificities were 91% and 92%, respectively. Positive predictive values were 81% (sites) and 71% (studies), and negative predictive values 95% (sites and studies). Thus, gallium scintigraphy proved to be a sensitive and specific method for staging and follow-up in patients with small, non-cleaved cell lymphoma.

Key words

Small non-cleaved cell (Burkitt's) lymphoma Gallium scintigraphy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Levine PH, Connelly RR, McKay FW. Burkitt's lymphoma in the USA: cases reported to the American Burkitt's lymphoma registry compared with population-based incidence and mortality data. In: Lenoir GM, O'Connor GT, Olweny CLM, eds. Burkitt's lymphoma: a human cancer model. Lyon: IARC Scientific Publications No. 60; 1985:217–224.Google Scholar
  2. 2.
    Horn NL, Ray GR, Kriss JP. Gallium-67 citrate scanning in Hodgkin's disease and non-Hodgkin's lymphoma. Cancer 1976; 37:250–257.Google Scholar
  3. 3.
    Andrews GA, Hubner KF, Greenlaw RH. Ga-67 citrate imaging in malignant lymphoma: final report of cooperative group. J Nucl Med 1978; 19:1013–1019.Google Scholar
  4. 4.
    Halpern S, Hagan P. Gallium-67 citrate imaging in neoplastic and inflammatory disease. In: Freeman LM, Weissmann HS, eds. Nuclear medicine annual 1980. New York: Raven; 1980:219–265.Google Scholar
  5. 5.
    Bekerman C, Hoffer PB, Bitran JD. The role of gallium-67 in the clinical evaluation of cancer. Sem Nucl Med 1984; XIV:296–323.Google Scholar
  6. 6.
    Richman SD, Appelbaum F, Levenson SM, Johnston GS, Ziegler JL. 67Ga radionuclide imaging in Burkitt's lymphoma. Radiology 1975; 117:639–645.Google Scholar
  7. 7.
    Glass RBJ, Fernbach SK, Conway JJ, Shkolnik A. Gallium scintigraphy in Amerikan Burkitt lymphoma: accurate assessment of tumor load and prognosis. AJR 1985; 145:671–676.Google Scholar
  8. 8.
    Ziegler JL, Magrath IT, Deisseroth AB, et al. Combined modality treatment of Burkitt's lymphoma. Cancer Treat Rep 1978; 62:2031–2034.Google Scholar
  9. 9.
    Edwards CL, Hayes RL. Tumor scanning with Ga-67 citrate. J Nucl Med 1969; 10:103–105.Google Scholar
  10. 10.
    Cohen MD, Siddiqui A, Weetman R, Provisor A, Coates T. Hodgkin disease and non-Hodkin lymphomas in children: utilization of radiological modalities. Radiology 1986; 158:499–505.Google Scholar
  11. 11.
    Medeiros LJ, Picker LJ, Horning SJ, Warnke RA. Transferrin receptor expression by non-Hodgkin's lymphomas. Cancer 1988; 61:1844–1851.Google Scholar
  12. 12.
    Hattner RS, White DL. Gallium-67/stable gadolinium antagonism: MRI contrast agent markedly alters the normal biodistribution of gallium-67. J Nucl Med 1990; 31:1844–1846.Google Scholar
  13. 13.
    Hoffer P. Gallium: mechanisms. J Nucl Med 1980; 21:282–285.Google Scholar
  14. 14.
    Magrath IT, Sariban E. Clinical features of Burkitt's lymphoma in the USA. In: Lenoir GM, O'Connor GT, Olweny CLM, eds. Burkitt's lymphoma: a human cancer model. Lyon: IARC Scientific Publications No. 60; 1985:119–127.Google Scholar
  15. 15.
    Tumeh SS, Rosenthal DS, Kaplan WD, English RJ, Holman BL. Lymphoma: evaluation with Ga-67 SPECT. Radiology 1987; 164:111–114.PubMedGoogle Scholar
  16. 16.
    Larson SM, Milder MS, Johnston GS. Interpretation of the 67Ga photoscan. J Nucl Med 1973; 14:208–214.Google Scholar
  17. 17.
    Hibi S, Todo S, Imashuku S. Thymic localization of gallium-67 in pediatric patients with lymphoid and nonlymphoid tumors. J Nucl Med 1987; 28:293–297.Google Scholar
  18. 18.
    Sulavik SB, Yeh SDJ, Spencer RP. Radiogallium studies in Hodgkin's disease: examination for panda and lambda signs. NucCompact 1990; 21:185–188.Google Scholar
  19. 19.
    Bakshi SP, Parthasarathy KL. Combination of laxatives for cleansing of 67Ga-citrate activity in the bowel. J Nucl Med 1974; 15:470.Google Scholar
  20. 20.
    Zeman RK, Ryerson TW. The value of bowel preparation in Ga-67 citrate scanning: concise communication. J Nucl Med 1977; 18:886–889.Google Scholar
  21. 21.
    Israel O, Front D, Lam M et al. Gallium 67 imaging in monitoring lymphoma response to treatment. Cancer 1988; 61:2439–2443.Google Scholar
  22. 22.
    Kaplan WD. Residual mass and negative scintigraphy in treated lymphoma: When is the gallium scan really negative? [editorial] J Nucl Med 1990; 31:369–371.Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Dirk Sandrock
    • 1
  • Secondo Lastoria
    • 1
  • Ian T. Magrath
    • 2
  • Ronald D. Neumann
    • 1
  1. 1.Department of Nuclear Medicine, National Cancer InstituteNational Institutes of HealthBethesdaUSA
  2. 2.Pediatric Branch, Department of Clinical Investigations, National Cancer InstituteNational Institutes of HealthBethesdaUSA

Personalised recommendations